The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESSO 45 | High-risk melanoma shows increased sentinel lymph node positivity
Hesham Mohamed, MBBch, The Royal Marsden NHS Foundation Trust, London, UK, presents data from study investigating sentinel lymph node status and oncological outcomes in high-risk and low-risk cutaneous primary melanoma. The high-risk group demonstrated significantly worse disease-free and recurrence-free survival, with 30% higher sentinel lymph node positivity compared to the low-risk group. Sentinel lymph node biopsy findings substantially altered staging in the high-risk cohort, with many patients upstaged to stage 3C rather than the stage 2B–C classification they would have received without nodal assessment. This interview took place at the 2026 European Society of Surgical Oncology (ESSO) Annual Meeting in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Read more...